news

Latest News

View All

Personal Genome Diagnostics’ Expanded PlasmaSELECT™ 64 Is First Liquid Biopsy Pan-Cancer Profiling Panel to Include MSI Analyses for Immuno-Oncology

–First Liquid Biopsy Assay to Include Assessment of Microsatellite Instability Status (MSI), a Surrogate Marker for High Tumor Mutational Load, that Helps Identify Patients Most Likely to Benefit from Treatment with Immuno-Oncology Therapies such as Checkpoint Inhibitors––Accurately Identifies Clinically Actionable Genetic Alterations across Multiple Cancer Types from Blood or Plasma without the…